$6.990
+0.195 (+2.79%)Al cierre
Noticias de CV
Eventos de CV
CapsoVision's AI Highlights Receives FDA Clearance
CapsoVision announced that AI Highlights, its AI-assisted reading tool for the CapsoCam Plus system, received clearance from the U.S. Food and Drug Administration, FDA, on September 25, 2026.
Outlook Therapeutics Appoints Kevin Lundquist as CFO
Outlook Therapeutics (OTLK) announced the appointment of Kevin Lundquist as CFO, effective September 1. Lundquist most recently served as CFO of CapsoVision (CV). In connection with Lundquist's appointment, Lawrence Kenyon will step down as CFO effective September 1. Kenyon will continue to support the company as a non-executive employee through September 30.
CapsoVision Files $250M Mixed Securities Shelf
CapsoVision files $250M mixed securities shelf
CapsoVision Files to Sell 2.87M Shares of Common Stock
CapsoVision files to sell 2.87M shares of common stock for holders
CapsoVision Closes $14M Private Placement Financing
CapsoVision on Friday announced the closing of a $14M private placement in public equity financing pursuant to a securities purchase agreement entered into by the company with selected accredited investors on March 16, for such investors to purchase shares of common stock of the company. The company agreed to sell 2,867,089 shares of common stock of the company, with par value $0.001 per share, at $4.883 per share, which represents a 5% discount to the March 16 closing price, as per the terms of the agreement, the company said. CapsoVision said it expects to use the net proceeds from the private placement for general corporate purposes, including sales and marketing, research and development activities, general and administrative matters, and working capital. On Friday, CapsoVision also announced preliminary results, including fourth quarter revenue of $3.9M and full year 2025 revenue of $13.6M. As of December, 31, 2025, the company had preliminary cash, cash equivalents, restricted cash and investments of approximately $10.1M. Following the preliminary results and private placement, Roth Capital raised the firm's price target on CapsoVision to $11 from $7 and keeps a Buy rating on the shares. Shares of CapsoVision are up nearly 21% in morning trading to $8.30.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.